Long-COVID, Metabolic and Endocrine Disease.
Stefan R BornsteinDiana CozmaMargrit KamelMawieh HamadMohammad G MohammadNaveed A KhanMaha Saber AyadMohammad H SemreenCharlotte SteenblockPublished in: Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme (2022)
In the aftermath of the corona pandemic, long-COVID or post-acute COVID-19 syndrome still represents a great challenge, and this topic will continue to represent a significant health problem in the coming years. At present, the impact of long-COVID on our health system cannot be fully assessed but according to current studies, up to 40% of people who have been infected with SARS-CoV-2 suffer from clinically relevant symptoms of long-COVID syndrome several weeks to months after the acute phase. The main symptoms are chronic fatigue, dyspnea, and various cognitive symptoms. Initial studies have shown that people with overweight and diabetes mellitus have a higher risk of developing long-COVID associated symptoms. Furthermore, repeated treatment of acute COVID-19 and long-COVID with steroids can contribute to long-term metabolic and endocrine disorders. Therefore, a structured program with rehabilitation and physical activity as well as optimal dietary management is of utmost importance, especially for patients with metabolic diseases and/or long-COVID. Furthermore, the removal of autoantibodies and specific therapeutic apheresis procedures could lead to a significant improvement in the symptoms of long-COVID in individual patients.
Keyphrases
- sars cov
- coronavirus disease
- respiratory syndrome coronavirus
- physical activity
- public health
- healthcare
- type diabetes
- liver failure
- mental health
- body mass index
- systemic lupus erythematosus
- metabolic syndrome
- end stage renal disease
- risk assessment
- chronic kidney disease
- case report
- newly diagnosed
- respiratory failure
- hepatitis b virus
- extracorporeal membrane oxygenation
- aortic dissection
- drug induced
- human health
- insulin resistance
- smoking cessation
- glycemic control